{
    "root": "2fc67165-6847-7e82-e063-6294a90abadd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "OXCARBAZEPINE",
    "value": "20250307",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C YELLOW NO. 5",
            "code": "I753WB2F1M"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25741"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "OXCARBAZEPINE",
            "code": "VZI5B1W380",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ],
    "indications": {
        "text": "oxcarbazepine tablets indicated monotherapy adjunctive therapy treatment partial-onset seizures adults monotherapy treatment partial-onset seizures pediatric patients aged 4 years , adjunctive therapy pediatric patients aged 2 years partial-onset seizures .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults : initiate dose 600 mg/day , given twice-a-day adjunctive therapy : maximum increment 600 mg/day approximately weekly intervals . recommended daily dose 1200 mg/day ( 2.1 ) conversion monotherapy : withdrawal concomitant 3 6 weeks ; reach maximum dose oxcarbazepine tablets 2 4 weeks increments 600 mg/day weekly intervals recommended daily dose 2400 mg/day ( 2.2 ) initiation monotherapy : increments 300 mg/day every third day dose 1200 mg/day ( 2.3 ) initiate one-half usual starting dose increase slowly patients creatinine clearance < 30 ml/min ( 2.7 ) pediatrics : initiation 8 10 mg/kg/day , given twice-a-day . patients aged 2 < 4 years 20 kg , starting dose 16 20 mg/kg/day may considered . recommended daily dose dependent upon patient weight . adjunctive patients ( aged 2\u201316 years ) : patients aged 4 16 years , target maintenance dose achieved 2 weeks ( 2.4 ) . patients aged 2 < 4 years , maximum maintenance dose achieved 2 4 weeks exceed 60 mg/kg/day ( 2.4 ) conversion monotherapy patients ( aged 4\u201316 years ) : maximum increment 10 mg/kg/day weekly intervals , concomitant antiepileptic drugs completely withdrawn 3 6 weeks ( 2.5 ) initiation monotherapy patients ( aged 4\u201316 years ) : increments 5 mg/kg/day every third day ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "oxcarbazepine tablets , usp provided : 300 mg film-coated tablets : beige , film-coated , modified oval shaped tablet , scored sides , debossed `` b|293 `` one side plain side . ndc : 70518-2276-00 packaging : 30 1 blister pack store 20\u00b0-25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0- 30\u00b0c ( 59\u00b0 - 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container ( usp ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "oxcarbazepine tablets contraindicated patients known hypersensitivity oxcarbazepine components , eslicarbazepine acetate [ ( 5.2 , 5.3 ) ] .",
    "indications_original": "Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.",
    "contraindications_original": "Adults: initiate with a dose of 600 mg/day, given twice-a-day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) Conversion to Monotherapy: withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine tablets in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day ( 2.3 ) Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance <30 mL/min ( 2.7 ) Pediatrics: initiation with 8 to 10 mg/kg/day, given twice-a-day. For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight. Adjunctive Patients (Aged 2\u201316 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks ( 2.4 ). For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60 mg/kg/day ( 2.4 ) Conversion to Monotherapy for Patients (Aged 4\u201316 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be completely withdrawn over 3 to 6 weeks ( 2.5 ) Initiation of Monotherapy for Patients (Aged 4\u201316 Years): Increments of 5 mg/kg/day every third day ( 2.6 )",
    "warningsAndPrecautions_original": "Oxcarbazepine Tablets, USP are provided as:\n                  300 mg Film-Coated Tablets:\u00a0beige, film-coated, modified oval shaped tablet, scored on both sides, debossed \"B|293\" on one side and plain on the other side.\n                  NDC: 70518-2276-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20\u00b0-25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0- 30\u00b0C (59\u00b0 - 86\u00b0F) [see USP Controlled Room Temperature].\n                  Dispense in tight container (USP).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [\n \n  see\n  \n   Warnings and Precautions (5.2,\n  \n   5.3)\n                     ].",
    "drug": [
        {
            "name": "OXCARBAZEPINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ]
}